Transforming the $286 Billion Active Pharmaceutical Ingredient (API) market through a world-first process that turns sunlight and CO₂ into valuable medical compounds.
Lead the RevolutionThe world's Active Pharmaceutical Ingredients (API) are currently manufactured overseas through complex, toxic bacteria and yeast processes that are geopolitically fragile and prohibitively expensive.
By reprogramming microalgae, Algae Code Biotech turns sunlight and CO₂ into a high-margin, remarkable breakthrough in API production.
2026 EU and US BIOSECURE Act mandates require rapid onshoring. Algae Code eliminates reliance on vulnerable offshore hubs, protecting domestic healthcare from critical shortages.
Replacing 3.3 trillion liters of toxic wastewater with a zero-waste process. We turn sustainability into an 81% margin asset by eliminating toxic solvents and chemical sludge.
By leveraging a 1,000,000L GMP partner ecosystem, Algae Code executes high-end contract development without the burden of traditional biological infrastructure costs.
Our bio-library already includes 97 validated molecules ready for immediate contract development in Oncology, Antibiotics, Alkaloids, Nutraceuticals and Specialty Care.
Our proprietary "Master Key" unlocks stable, high-yield production in microalgae—a global first-to-market biological advantage over legacy platforms.
A disruptive fee-for-service model that delivers high-performance biological software with a 60% cost efficiency edge over legacy yeast and bacteria.
A 4-minute deep dive into the Algae Code platform and the future of onshore pharmaceutical sovereignty.
Algae Code Biotech is the solution, using its remarkable microalgae process to lead the global API revolution.
Seeking $2 Million for our 18-month runway to CDMO profitability. To request our full investor materials or initiate a contract partnership, reach out below.